A genomic study of 300 meningiomas showed mutations in TRAF7 in approximately 25% of all meningiomas, AKT1 mutations in 10-15% (affecting the PI3K signaling pathway) and KLF4 mutations in 10%. This evidence concerns the gene AKT1 and meningioma.